Navigation Links
PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
Date:2/7/2011

companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information: +34 91 444 4500

This note is also available on the PharmaMar web site: www.pharmamar.com and at Zeltia's web site: www.zeltia.com


'/>"/>
SOURCE PharmaMar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
8. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
11. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... United States, today announced its financial results for the ... Fourth-Quarter 2014 Highlights , Net Revenues Increased 21.3% ... Services Net Revenues Grew 17.7% Year Over Year to ...
(Date:3/5/2015)... and TÜBINGEN, Germany , ... Melinda Gates Foundation and CureVac today announced that ... $52 million (€46 million) in CureVac, a leading ... As part of the agreement, the foundation will ... develop prophylactic vaccines based on CureVac,s proprietary messenger ...
(Date:3/5/2015)... 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... ended January 31, 2015 on Thursday, March 12 before the ... results at 11:00 AM ET. To participate ... 10 minutes before the beginning of the call. If you ... will be available from Thursday, March 12, 2015 through midnight ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... ... Salt Lake City based software company, announces the launch of a new ... in conjunction with existing in-office therapy methods. , eyeQ was ... elect, Dr. Brad Habermehl believes the eyeQ program adds significant ...
... , FRANKLIN, Mass., Nov. 24 ... company developing its needle-free Symphony(TM) tCGM System as a ... its Prelude(TM) SkinPrep System for transdermal drug delivery, announced ... Executive Officer, will present at the 13th Annual Biotech ...
Cached Medicine Technology:Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2
(Date:3/6/2015)... Jvion, the Atlanta-based leader in ... Clostridium Difficile (C Diff) predictive use case for ... case is the latest in a broad compliment ... chronic conditions, and individual illnesses. Using the firm’s ... flags at risk individuals to help support clinician ...
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 Yisrayl ... in Abilene, Texas, has released a new publication explaining ... working. , The article titled “Microorganisms Do ... document explaining how tiny microorganisms were created and designed ... is aware of some of the functions of these ...
(Date:3/6/2015)... Springs, FL (PRWEB) March 06, 2015 The ... present March 2015 air dates for Spokane, Washington and vicinity. ... colorful places to shop and dine, and many outdoor activities. ... industry supporting the local economy. Six major hospitals call the ... to the Canadian border. The medically-focused cable TV program will ...
(Date:3/6/2015)... March 06, 2015 The Public ... awarded five-year accreditation status to seven more health departments. ... another 1.3 million people can now be assured that ... promote the health of their communities. , Public health ... the health of people and communities. Across the nation, ...
(Date:3/5/2015)... 2015 This week, 60 ... low-cost laminate flooring products, initiating widespread concern from ... building materials made primarily from bamboo, stands behind ... their flooring products for volatile organic compounds (VOCs) ... International (BMH). Results from formaldehyde emissions testing ...
Breaking Medicine News(10 mins):Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2
... -- The role that air pollution plays in heart ... be underestimated, according to researchers. A small study ... changes in the heart,s electrical system when the participants ... that air pollution may interfere with the heart,s ability ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... people walk may provide a glimpse into how many years ... that a formula that includes gait predicted older people,s future ... health conditions as blood pressure and heart disease. Walking ...
... for the 2013 America,s Cup has been announced, a study ... smooth sailing. The study was published recently in the journal ... survey completed by sailors, researchers at Rhode Island Hospital have ... two types of boats -- dinghies (small boats with crews ...
... TUESDAY, Jan. 4 (HealthDay News) -- Rates of head and ... young women without any known risk factors. Now, a study ... the movement of precancerous cells in the mouth. ... estrogen after the lungs are exposed to smoke. This may ...
... 2011 - Normally, cortical nerve cells or neurons reside in ... in the white matter, but some people with schizophrenia have ... migration errors may arise in schizophrenia as a consequence of ... aberrant cellular localization has now been studied in detail in ...
... the leading cause of death in the developed world. ... have been defined, scientists continue to study other possible ... studies link infectious agents with the development of inflammatory ... pathogen Porphyromonas gingivalis is the induction of ...
Cached Medicine News:Health News:Fast Walkers May Have More Years Ahead of Them 2Health News:Fast Walkers May Have More Years Ahead of Them 3Health News:Watch out for that boom 2Health News:Watch out for that boom 3Health News:Estrogen May Play Role in Rising Rates of Head, Neck Cancer 2Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Porphyromonas gingivalis accelerates inflammatory atherosclerosis in a mouse model 2
... The unparalleled Humphrey Lens Analyzers ... SPEXAN provide the most comprehensive lensometry ... the Humphrey Lens Analyzer (LA) gives ... for any lens-progressive lenses, prism lenses, ...
Lens Loading and Folding for Multipiece & Single-Piece ACRYSOF Lens with Standard Forceps...
... The Laserex Ultra Q is a hospital ... provides ophthalmologists with a precise, reliable means ... membranectomy. The system can be used ... opacification of the capsule (posterior capsulotomy), and ...
... The Laserex Super Q is an ... a precise and reliable means for performing ... The Super Q delivers benchmark performance in ... ,The Laserex Super Q produces a ...
Medicine Products: